PREVIEW ASH 2026 — New Orleans, Dec 12–15: the abstracts hematologists are watching, top voices and trial buzz See the ASH 2026 preview →

5 min read

The $SMMT Blame Game: The Sources and Context Behind Every Quote

The $SMMT Blame Game: The Sources and Context Behind Every Quote

KOL Pulse’s “$SMMT Blame Game” infographic sets what Summit Therapeutics’ leaders said at each HARMONi setback next to what the data, the invited discussants and, per Summit, the FDA said. This post gives the source and the context for every quote on it.

On November 15, 2026, Summit announced a Complete Response Letter for ivonescimab plus platinum chemotherapy in EGFR-mutant non-squamous NSCLC after EGFR TKI, based on the global Phase 3 HARMONi trial (Summit release). For the full trial story, see From ASCO24 Hype to FDA CRL Reality and the HARMONi trial profile.

The $SMMT Blame Game infographic: Summit leadership quotes on HARMONi accrual, the WCLC 2025 and ASCO 2026 HARMONi-6 discussants, and what the FDA cited in the Nov 15, 2026 CRL, per Summit
The $SMMT Blame Game. Commentary and opinion by KOL Pulse.

Three trials, three settings

  • HARMONi-A (NCT05184712): Akeso’s China-only Phase 3, ivonescimab + chemo vs placebo + chemo, EGFR-mutant non-squamous NSCLC after EGFR TKI. PFS was the only primary endpoint. Presented at ASCO 2024; approved in China in this setting in May 2024.
  • HARMONi (NCT06396065): Summit’s global Phase 3 in the same setting, with PFS and OS as dual primary endpoints. 438 patients: 273 (62%) enrolled in Asia and 165 in North America and Europe. This is the trial behind the BLA and the CRL.
  • HARMONi-6: Akeso’s China-only Phase 3 of first-line ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC. Interim OS was presented at the ASCO 2026 plenary. It is a different population and setting from the trial in the CRL.

1. Slow Western accrual and the OS miss (2025)

Bob Duggan, Chairman & Co-CEO, Summit Therapeutics

“all of us underestimated the level of conservatism and caution amongst North American physicians … with regard to China data. This was a first. It took quite a bit of time to gather momentum to get off the tarmac, so to speak, and into the air.”

When and where: Summit’s investor call on September 8, 2025, after the HARMONi presentation at WCLC 2025. Sources: stockanalysis.com transcript; PharmCube transcript. The two transcripts agree on substance; “This was a first. It took” appears in the stockanalysis.com version.

Context: Duggan was explaining why HARMONi took longer to complete. Just before this, he said the FDA had “leaned in and allowed us to include China data”; the words removed at the … refer to caution about bispecifics being novel. At WCLC 2025, the primary OS analysis showed HR 0.79 (95% CI 0.62–1.01), P=0.057, short of the P≤0.0448 needed for significance. Median follow-up was 29.7 months overall but 9.2 months for patients in North America and Europe.

Dr. Maky Zanganeh, President & Co-CEO, Summit Therapeutics

“We enrolled, we started the enrollment as soon as possible. For sure, at this moment of time as well, it was a time that we take a little bit to everybody questioning what is the bispecific, everybody questioning what is the China data. Everybody, it just was so much questions.”

When and where: Goldman Sachs 46th Annual Global Healthcare Conference, June 9, 2025. Source: stockanalysis.com transcript (third-party transcript).

Context: Dr. Zanganeh was explaining how HARMONi was built. She said the study “was already enrolled in China. When we did the deal with Akeso, which was around February 2023, we started right away, we were in discussion with the FDA. For sure, the discussion was to add additional patients into the Chinese patient populations.”

2. The WCLC 2025 discussant

Dr. Suresh Ramalingam, Winship Cancer Institute of Emory University, invited discussant of HARMONi at WCLC 2025

“No clear evidence of PD-1 blockade as a contributor to efficacy”

Source: his “Taken together” discussion slide at WCLC 2025, also reported by Fierce Pharma (September 10, 2025). The same slide says the PFS benefit in HARMONi “is comparable to studies that have evaluated VEGF inhibitors in NSCLC” and that “in EGFRMT NSCLC its MoA (dual blockade) does not appear to offer an advantage.”

Dr. Jack West, VP, Clinical Development, Summit Therapeutics

“his view was about as far in the negative range of the confidence intervals of fairness as you could get”

When and where: Summit’s September 8, 2025 investor call. Sources: stockanalysis.com transcript; PharmCube transcript.

Context: Dr. West was responding to Dr. Ramalingam’s WCLC discussion. He first said “no one would ever say that Dr. Ramalingam is not knowledgeable or unfair necessarily,” and finished the sentence “within the admittedly ambiguous setting of the trial,” calling the view “quite uncharitable.” Per Fierce Pharma, he argued that Dr. Ramalingam minimized the relative immaturity of the original OS data. Fierce also reported that Dr. Ramalingam said he would not attach much significance to the nominal P-value from the longer OS follow-up because it was not part of the trial’s design.

3. ASCO 2026: the HARMONi-6 plenary (a different trial)

Dr. Julie Brahmer, Johns Hopkins, invited discussant of HARMONi-6 at ASCO 2026

“Right now, I would say no, it’s not applicable to the global patient population.”

Source: interview with Fierce Biotech (May 31, 2026).

Context: Dr. Brahmer was discussing HARMONi-6, Akeso’s China-only first-line squamous NSCLC trial, not the EGFR-mutant HARMONi trial behind the CRL. Per Fierce, HARMONi-6 met its interim OS endpoint (median 27.9 vs 23.7 months, a 34% reduction in the risk of death, P=0.0017). Dr. Brahmer called the result “provocative” and raised the short follow-up, the exclusion of patients over 75, a hazard ratio near 1 in patients over 65, and enrollment of almost all men. She also said “We really do need that next wave of Harmoni studies.”

Dr. Maky Zanganeh, President & Co-CEO, Summit Therapeutics

“the big debate between China, China data, and everything related coming from China … So this debate I’m not very comfortable with”

When and where: BiotechTV interview with Brad Loncar, June 1, 2026, the day after the HARMONi-6 plenary. Sources: BiotechTV on X; BiotechTV episode page (video; quote transcribed from the recording).

Dr. Allen Yang, Chief R&D Strategy Officer, Summit Therapeutics

“Summit has a tradition of drawing very tough sort of discussants”

When and where: Goldman Sachs 47th Annual Global Healthcare Conference, June 8, 2026. Source: stockanalysis.com transcript (third-party transcript; the sentence continues “in our presentations”). The transcript lists Dr. Yang as Chief Medical Officer; the infographic uses his current title.

Context: The conference came a week after the HARMONi-6 plenary. Dr. Yang said physicians he spoke with after the meeting were “very excited about Ivo,” then made this remark and added: “I think she sort of missed the point of that presentation.” In a later answer, on HARMONi-3 and baseline imbalances, he said Chinese studies commonly cap enrollment at 75 and that the hazard ratio in older patients in HARMONi-6 was “still under one.”

4. What the FDA cited, per Summit

“The CRL indicates that the BLA cannot be approved in its present form, as the FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (OS) improvement.”

Source: Summit release, November 15, 2026. The release adds that the FDA indicated the PFS benefit without a statistically significant OS benefit “does not support a positive benefit-risk profile in support of approval.” The FDA’s letter itself has not been posted. Summit’s release also states: “Currently, there are no FDA-approved regimens that have demonstrated a statistically significant OS benefit in this patient setting,” and cites a post hoc analysis with longer follow-up of Western patients showing an OS hazard ratio of 0.76 in the full population, Asian patients and Western patients. The earlier September 2025 longer-follow-up cut, shown at WCLC 2025, reported HR 0.78 overall (nominal P=0.0332), 0.84 in Western patients and 0.76 in Asian patients (Summit, November 2025). Neither was a formally tested result.

Notes on the quotes

  • Quotes are verbatim from the sources linked. “…” marks words removed.
  • The Duggan, Zanganeh (June 2025) and Yang quotes come from third-party transcripts of investor events, not from Summit-published transcripts.
  • The Brahmer quote is from her interview with Fierce Biotech.
  • Ivonescimab is investigational in the US. It is approved in China.

More on HARMONi, with slides and physician posts: HARMONi trial profile on KOL Pulse.